23 May 2013
Keywords: devgen, sees, good, data, trials, oral, tnf
Article | 28 August 2006
Belgian biotechnology firm Devgen says that preclinical trials of a series of compounds, that inhibit tumor necrosis factor alpha, have
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 August 2006
© 2013 thepharmaletter.com